Carmen Vicente

Carmen Vicente

Auto-generated profile, based on publicly available information

Carmen Vicente

KU Leuven Center for Human Genetics, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KKKim De Keersmaecker
Kim De Keersmaecker
ZAZeynep Kalender Atak
Zeynep Kalender Atak
NLNing Li
Ning Li
CVCarmen Vicente
Carmen Vicente
SPStephanie Patchett
Stephanie Patchett
JCJan Cools
Jan Cools

2 March 2017 in Blood
Verified
Journal Article
Open access
PDF file
TGTiziana Girardi
Tiziana Girardi
CVCarmen Vicente
Carmen Vicente
JCJan Cools
Jan Cools
KKKim De Keersmaecker
Kim De Keersmaecker
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy caused by the accumulation of genomic lesions that affect the development of T cells. For many years, it has been established that deregulated expression of transcription factors, impairment of the CDKN2A/2B cell-cycle regulators, and hyperactive NOTCH1 signaling play prominent roles in the pathogenesis of this leukemia. In the past decade, systematic screening of T-ALL genomes by high-resolution copy-number arrays and next-generation sequencing technologies has revealed that T-cell progenitors accumulate additional mutations affecting JAK/STAT signaling, protein translation, and epigenetic control, providing novel attractive targets for therapy. In this review, we provide an update on our knowledge of T-ALL pathogenesis, the opportunities for the introduction of targeted therapy, and the challenges that are still ahead.

1 November 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMarta M. Alonso
Marta M. Alonso
RDRicardo Diez-Valle
Ricardo Diez-Valle
LMLorea Manterola
Lorea Manterola
ARAngel Rubio
Angel Rubio
DLDan Liu
Dan Liu
CGCandelaria Gomez-Manzano
Candelaria Gomez-Manzano
We undertook this study to understand how the transcription factor Sox2 contributes to the malignant phenotype of glioblastoma multiforme (GBM), the most aggressive primary brain tumor. We initially looked for unbalanced genomic rearrangements in the Sox2 locus in 42 GBM samples and found that Sox2 was amplified in 11.5% and overexpressed in all the samples. These results prompted us to further investigate the mechanisms involved in Sox2 overexpression in GBM. We analyzed the methylation status of the Sox2 promoter because high CpG density promoters are associated with key developmental genes. The Sox2 promoter presented a CpG island that was hypomethylated in all the patient samples when compared to normal cell lines. Treatment of Sox2-negative glioma cell lines with 5-azacitidine resulted in the re-expression of Sox2 and in a change in the methylation status of the Sox2 promoter. We further confirmed these results by analyzing data from GBM cases generated by The Cancer Genome Atlas project. We observed Sox2 overexpression (86%; N = 414), Sox2 gene amplification (8.5%; N = 492), and Sox 2 promoter hypomethylation (100%; N = 258), suggesting the relevance of this factor in the malignant phenotype of GBMs. To further explore the role of Sox2, we performed in vitro analysis with brain tumor stem cells (BTSCs) and established glioma cell lines. Downmodulation of Sox2 in BTSCs resulted in the loss of their self-renewal properties. Surprisingly, ectopic expression of Sox2 in established glioma cells was not sufficient to support self-renewal, suggesting that additional factors are required. Furthermore, we observed that ectopic Sox2 expression was sufficient to induce invasion and migration of glioma cells, and knockdown experiments demonstrated that Sox2 was essential for maintaining these properties. Altogether, our data underscore the importance of a pleiotropic role of Sox2 and suggest that it could be used as a therapeutic target in GBM.

1 April 2012 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
CVCarmen Vicente
Carmen Vicente
ACAna Conchillo
Ana Conchillo
AGAsuncion Garcia-Sanchez
Asuncion Garcia-Sanchez
MOMaría D. Odero
María D. Odero

21 January 2010 in Blood
Verified
Journal Article
Closed access
PDF file
ICIon Cristóbal
Ion Cristóbal
Francisco BlancoFrancisco Blanco
Francisco Blanco
LGLaura Garcia-Orti
Laura Garcia-Orti
NMNerea Marcotegui
Nerea Marcotegui
CVCarmen Vicente
Carmen Vicente
MOMaría D. Odero
María D. Odero
Acute myeloid leukemias (AMLs) result from multiple genetic alterations in hematopoietic stem cells. We describe a novel t(12;18)(p13;q12) involving ETV6 in a patient with AML. The translocation resulted in overexpression of SETBP1 (18q12), located close to the breakpoint. Overexpression of SETBP1 through retroviral insertion has been reported to confer growth advantage in hematopoietic progenitor cells. We show that SETBP1 overexpression protects SET from protease cleavage, increasing the amount of full-length SET protein and leading to the formation of a SETBP1–SET-PP2A complex that results in PP2A inhibition, promoting proliferation of the leukemic cells. The prevalence of SETBP1 overexpression in AML at diagnosis (n = 192) was 27.6% and was associated with unfavorable cytogenetic prognostic group, monosomy 7, and EVI1 overexpression (P < .01). Patients with SETBP1 overexpression had a significantly shorter overall survival, and the prognosis impact was remarkably poor in patients older than 60 years in both overall survival (P = .015) and event-free survival (P = .015). In summary, our data show a novel leukemogenic mechanism through SETBP1 overexpression; moreover, multivariate analysis confirms the negative prognostic impact of SETBP1 overexpression in AML, especially in elderly patients, where it could be used as a predictive factor in any future clinical trials with PP2A activators.

23 July 2015 in Haematologica
Verified
Journal Article
Open access
PDF file
CVC. Vicente
C. Vicente
CSC. Schwab
C. Schwab
MBM. Broux
M. Broux
EGE. Geerdens
E. Geerdens
SDS. Degryse
S. Degryse
JCJan Cools
Jan Cools
T-cell acute lymphoblastic leukemia is caused by the accumulation of multiple oncogenic lesions, including chromosomal rearrangements and mutations. To determine the frequency and co-occurrence of mutations in T-cell acute lymphoblastic leukemia, we performed targeted re-sequencing of 115 genes across 155 diagnostic samples (45 adult and 110 childhood cases). NOTCH1 and CDKN2A/B were mutated/deleted in more than half of the cases, while an additional 37 genes were mutated/deleted in 4 to 20% of cases. We identified the IL7R-JAK pathway to be mutated in 27.7% of cases, with JAK3 mutations being the most frequent event in this group. Copy number variations were also detected, including deletions of CREBBP or CTCF and duplication of MYB. FLT3 mutations were rare, but a novel extracellular mutation in FLT3 was detected and confirmed to be transforming. Furthermore, we identified complex patterns of pairwise associations, including a significant association between mutations in IL7R-JAK genes and epigenetic regulators (WT1, PRC2, PHF6). Our analyses showed that IL7R-JAK genetic lesions did not confer adverse prognosis in T-cell acute lymphoblastic leukemia cases enrolled in the UK ALL2003 trial. Overall, these results identify interconnections between the T-cell acute lymphoblastic leukemia genome and disease biology, and suggest a potential clinical application for JAK inhibitors in a significant proportion of T-cell acute lymphoblastic leukemia patients.